Metabolic transformation (Phase I) is :

RRB Staff Nurse Ahmedabad-2015

Pharmacology

Easy

Appeared in: RRB Staff Nurse Ahmedabad-2015

Explanation

Phase I metabolism, also known as nonsynthetic or functionalization reactions, prepares drugs for excretion by making them more polar.
It primarily involves three types of chemical reactions: oxidation, reduction, and hydrolysis.
These reactions introduce or unmask a polar functional group (like -OH or -NH2) on the drug molecule.
This process increases the drug's water solubility, which facilitates its elimination by the kidneys.
The primary enzyme system responsible for most Phase I reactions is the Cytochrome P-450 (CYP450) system, which is highly concentrated in the liver.

Option A: Acetylation and methylation are types of Phase II (conjugation) reactions, not Phase I.
Option C: Glucuronide formation (glucuronidation) is the most common type of Phase II (conjugation) reaction.
Option D: Binding to plasma proteins is a process of drug distribution within the body, not a metabolic transformation.

Visual 1: Diagram: Illustrating the two phases of drug metabolism. Phase I (oxidation, reduction, hydrolysis) is shown converting a lipophilic drug into a more polar metabolite, which then enters Phase II (conjugation) to become a water-soluble compound ready for excretion.
Visual 2: Flowchart: Showing the pathway of a drug from administration to excretion, highlighting the roles of the liver, Cytochrome P-450 enzymes, and the kidneys in Phase I and Phase II metabolism.

Clinical Relevance

Nursing practice connection: This is primarily an exam-oriented knowledge point with limited direct bedside application, so retain Phase I of drug metabolism (biotransformation) as background academic context rather than a clinical decision trigger.
Understanding drug metabolism is crucial for safe medication administration, as it determines drug dosage, frequency, and the potential for drug-drug interactions.
Factors like age (infants and the elderly have reduced metabolic capacity), liver disease, and genetic variations in CYP enzymes can significantly alter a patient's response to a standard drug dose, increasing the risk of toxicity or therapeutic failure.
What if? A patient is a known 'poor metabolizer' for a specific CYP enzyme and is given a drug primarily cleared by that enzyme. The nurse should anticipate the need for a lower dose to prevent accumulation and toxicity, and monitor closely for adverse effects.

How to Approach the Question

First, identify the core concept of the question, which is 'Phase I' of 'metabolic transformation' (drug metabolism).
Recall the two main phases of drug metabolism: Phase I (functionalization/nonsynthetic) and Phase II (conjugation/synthetic).
Remember the key reactions for each phase. Phase I involves oxidation, reduction, and hydrolysis.
Phase II involves adding a molecule to the drug, such as glucuronide, acetate, or a methyl group.
Evaluate the options based on this knowledge. 'Oxidation, reduction, or hydrolysis' directly matches the definition of Phase I reactions.
Eliminate the other options by identifying them as either Phase II reactions (acetylation, methylation, glucuronide formation) or a different pharmacokinetic process (protein binding).

Concept Tested & Keywords

QsJcjuuqV9HERH5j0vMLvQ